ทวีตที่ปักหมุด
$NVAX Biotech Analysis Central "Novavax Continues Progress: Latest COVID-19 Data Shows Encouraging Signs Of Advancement" seekingalpha.com/article/437077…
English
Terry Chrisomalis
505 posts
Terry Chrisomalis
@BioAnalysisCent
Founder of "Biotech Analysis Central" marketplace at Seeking Alpha, Biotech author at Seeking Alpha Journalist of Biotech, Follow me on Stocktwits BiopharmaPro
เข้าร่วม Mayıs 2018
2K กำลังติดตาม725 ผู้ติดตาม
Terry Chrisomalis รีทวีตแล้ว
$ABUS - The Patent Office issued ABUS it's newest patent this morning. IMO, the new patent covers both the $MRNA and $PFE / $BNTX vaccines. It has an effective filing date (for prior art) dating back to 2009.
Patent Pundit@PunditPatent
In addition to covering the $MRNA Covid Vaccine, it looks like the new patent application that $ABUS got allowed on August 30, 2021 (app. no. 17/227802) also covers the Pfizer-BioNTech Covid Vaccine.
English
$CLDX "Celldex's Latest Data For Chronic Inducible Urticaria Drug Is Only The Beginning" seekingalpha.com/article/443892…
English
$ABUS "Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment" seekingalpha.com/article/443707…
English
$ABUS Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection biospace.com/article/releas…
English
$ABUS "Arbutus Announces New Data On Ab-729 And Ab-836 Programs With Presentation Of Five Abstracts At The Easl International Liver Congress™ 2021 - All Selected For Best Of Ilc™" globenewswire.com/news-release/2…
English
$EPZM "Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge" #comment-89292337" target="_blank" rel="nofollow noopener">seekingalpha.com/article/443608…
English
$ABUS "Biotech Analysis Central Preview Series: Arbutus Biopharma" seekingalpha.com/instablog/1058…
Lietuvių
Terry Chrisomalis รีทวีตแล้ว
$ABUS #HBV $ARWR $VIR $DRNA investor.arbutusbio.com/news-releases/…
Dirk Haussecker@RNAiAnalyst
$ABUS Excellent: giving #HBV RNAi compound AB-729 every 8 weeks same efficacy as every 4 weeks. Benefit not just patient convenience, but better liver safety. -->Indeed, liver safety profile in 8 week cohort better than in 4 week. $ARWR $VIR $DRNA
QME
@RNAiAnalyst $ABUS Recent HBV data, but more importantly another catalyst. They still releasing AB-729 60 mg multi-dose every 8-weeks dose. If they can prove up to every 8 weeks or every 12-weeks that would be huge for Hep B treatment. This is coming any day now Q4 2020.
English
@biot_notes @MedResCol Read the data The final 16 weeks multi-dose did not reach plateau. 3 patients still getting -1.73 and still declining. That is only 16 weeks. You can't compare the other companies which have observed 24 weeks or 48 weeks. That fast of a decline in HBV in that short of a time good
English
@MedResCol 1-1.5 log reduction seems a bit weak, doesn't it? What gives you confidence relative to some of the other drugs in development?
English
$ABUS Impressed that the 60 mg AB-729 multi-dose (once every 4 weeks) hasn't reached a plateau past 16 weeks. Mean reduction of -1.44 log IU/ML at week 16 in Hepatitis B patients, no plateau yet past week 16.
English
$ABUS Going to present at AASLD On Sunday November 15, 2020 , with press release afterwards on results. Monday November 16th conference call to discuss data. First look at 60 mg AB-729 multi-dose cohort, plus long-term single dose cohorts of 60 mg and 90 mg of AB-729 for Hep B
English
Terry Chrisomalis รีทวีตแล้ว
$ABUS tempted to buy here on weakness ahead of HBV RNAi multi-dose presentation at AASLD;
but then again: if data good, they'll sell more shares.
English
$VRTX $MRNA Biotech Analysis Central "Vertex Looks To Target 10% Of Cystic Fibrosis Population Not Yet Achieved By Its Current CFTR Modulators" seekingalpha.com/article/437861…
English
$CRDF Biotech Analysis Central "Cardiff Oncology's Onvansertib Could Possibly End Up Being A Solid Cancer Drug" seekingalpha.com/article/437859…
English
$MRTX Biotech Analysis Central "Mirati Will Continue To Shine As It Keeps Delivering Promising Results" seekingalpha.com/article/437856…
English
$ALX $MRK $GILD $TRIL Biotech Analysis Central "ALX Oncology Is A Promising CD47 Targeting Biotech With Massive Potential" seekingalpha.com/article/437603…
English